Τόμος 19 (2001) – Τεύχος 2 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 19 (2001) – Issue 2 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Κωνσταντίνος Τρούγκος

Εργαστήριο Βιολογικής Χημείας, Ιατρική Σχολή,  Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάς

Constantinos Troungos

Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece

2. Hunter T., Pines J.: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582 (1994)

3. Pardee A.B.: A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci USA 71: 1286-1290 (1974)

4. Elledge S.J.: Cell cycle checkpoints: preventing an iden­tity crisis. Science 274: 1664-1672 (1996)

5. Weinberg R.A.: The retinoblastoma protein and cell cycle control. Cell 81: 323-330 (1995)

6. Lundberg A.S., Weinberg R.A.: Functional inactivation of retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 18: 753-761 (1996)

7. Nevins J.R.: Towards and understanding of the func­tional complexity of the E2F and retinoblastoma families. Cell Growth Different 9: 585-593 (1998)

8. Leone G., De Gregori J., Sears R., Jakoi L., Nevins J.R. : Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387: 422-426 (1997)

9. Polyak K., Lee M.H., Erdjument-Bromage H., et al.: Cloning of p27Kip 1, a cyclin – dependent kinase inhibitor and a potential mediator of extracellular antimitogenic sig­nals. Cell 78: 59-66 (1994)

10. Bos J.L.: Ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689 (1989)

11. Weinberg R.A.: Tumor suppressor genes. Science 254: 1138-1146 (1991)

12. Munger K.: The molecular biology of cervical cancer. J. Cell Biochem. 23(Suppl.): 55-60 (1995)

13. Giaccia A.J., Kastan M.B.: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev.12: 2973-2983 (1998)

14. Agarwal M.L., Agarwal A., Taylor W.R., Stark G.R.: P53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92: 8493-8497 (1995)

15. Qin X.Q., Livingston D.M., Kaelin Jr W.G., Adams P.D.: Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91: 10918-10922 (1994)

16. Dynlacht B.D., Moberg K., Lees J.A., Harlow H., Zhu L.: Specific regulation of E2F family members by cyclin-de­pendant kinases. Mol. Cell Biol. 17: 3867-3875 (1997)

17. Bates S., Phillips A.C., Clark P.A., et al.: E2F-1 regula­tion of p14^ARF links pRB and p53. Nature 395: 124-125 (1998)

18. Tsai K.Y., Hu Y., MacLeod K.F., Crowley D., Yamasaki L., Jacks T.:  Mutaion of E2F-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 2: 293-304 (1998)

19. De Gregori J., Leone G., Miron A., Jakoi L., Nevins J.R.: Distinct roles for E2F proteins in cell growth control and apoptosis. Rroc. Natl. Acad. Sci. USA 94: 7245-7250 (1997)

20. Yu D., Jing T., Liu B., et al.: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p212^Cip1 which inhibits p342^Cdc2 kinase. Mol. Cell 2: 581-591 (1998)

21. Κιτράκη E., Τρούγκος K.: Βιολογία του καρκίνου. Ιατρικές εκδόσεις Π. Χ. Πασχαλίδης, Αθήνα, 1999

22. Newbold R.F., Overell R.W.: Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304: 648-651 (1983)

23. Evan G.I., Wyllie A.H., Gilbert C.S., et al.: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128 (1992)

24. Pomerantz J., Schreiber-Agus N., Liegeois N.J., et al.: The Ink4a tumor suppressor gene product p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92: 713-723 (1998)

25. Zhang Y., Xiong Y., Yarbrourgh W.G.: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734 (1998)

26. Kamijio T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J.: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Rroc. Natl. Acad. Sci. USA 95: 8292-8297 (1998)

27. Ruas M., Peters G.: The p162^INK4A//CDKN2A tumor suppressor and its relatives. Biochem. Biophys. Acta Rev. Cancer (1998)

28. Lane D.P.: Cancer. P53, guardian of the genome. Na­ture 358: 15-16 (1992)